The most important consideration when evaluating a therapy for any disease is to determine whether the therapy is based on incontrovertible scientific facts. McGraw-Hill Co; 2008. In conclusion, the studies demonstrate that long-term anti-veg therapy and more frequent monitoring is necessary to control macular enema in many patients with CRVO, likely because the continued ischemia leads to continued excessive VEGF production. 29, 19, 30, 31, 32 Intravitreal Injection of bevacizumab Avastin, Genentech, Inc. is a recombinant, humanized monoclonal antibody that binds all isoforms of VEGF-A. This procedure is typically performed in the office. February 2010. This gives us a clear, precise image. Benefit from bevacizumab for macular enema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Press release issued by the company in September 2012. No ocular therapy has been proven to help. Klein R, Klein BE, Moss CSE, Meier FM.
act Ophthalmol sand 2002;80:355-67. The prevalence of CRVO was 0.8 per 1,000. The success rate is low, and the complication rate can be quite high, including vitreous haemorrhages and choroid al neovascularization at the anastomosis site.